Innorna Co., a Chinese mRNA drug developer backed by buyout firm CDH Investments, is planning a Hong Kong IPO, Bloomberg reported, citing informed sources.

Sources disclosed that Innorna is collaborating with CICC and Jefferies on a potential share offering, which could take place as early as next year.

One of the sources also mentioned that Innorna might raise about USD200 million through the IPO, though details like the size and timetable are still preliminary and subject to change.